BRAF and lung adenocarcinoma: Genomic biomarkers paired with targeted therapies have proven highly efficacious in some cases, such as HER2 amplification and trastuzumab in breast cancer [93], BRAF mutation and combined BRAF/MEK inhibition in melanoma [94] and EML4-ALK fusions and Crizotinib in lung adenocarcinoma [95].